不可逆表皮生长因子受体酪氨酸激酶抑制剂研究进展  

Advances in Research on Irreversible EGFR Tyrosine Kinase Inhibitors

作　　者：陶卓[1] 程海博[1] 周金培[1] 张惠斌[1] 

机构地区：[1]中国药科大学新药研究中心,江苏南京210009

出　　处：《药学进展》2013年第6期241-248,共8页Progress in Pharmaceutical Sciences

基　　金：江苏省产学研联合创新资金--前瞻性联合研究项目(No.BY2011158);国家"重大新药创制"科技重大专项资助项目(No.2013ZX09301303-002)

摘　　要：表皮生长因子受体具有酪氨酸激酶活性,其与表皮生长因子结合后可启动细胞核内的相关基因,促进细胞分裂增殖,多种肿瘤中均可见该受体水平异常升高。近年来,表皮生长因子受体酪氨酸激酶抑制剂的开发已成为肿瘤治疗领域中的研究热点。综述了不可逆表皮生长因子受体酪氨酸激酶抑制剂的研究进展,旨在为该类抗肿瘤药物的进一步开发提供参考。[ Abstract] Epidermal growth factor （EGF） receptor （EGFR）, which has tyrosine kinase activity, is an important mediator responsible for cell proliferation and differentiation. The binding of EGF and EGFR can activate the related genes in cell nuclear, so as to promote cell division and proliferation. The abnor- mal increase of EGFR level can be observed in many kinds of tumors. Recently, the development of EGFR tyrosine kinase inhibitors has become a research hotspot in the field of tumor therapy. The advances in research on irreversible EGFR tyrosine kinase inhibitors have been reviewed in this paper, in order to provide references for the further development of new antitumor drugs.

关 键 词：抗肿瘤 迈克尔受体 酪氨酸激酶抑制剂 表皮生长因子受体 

分 类 号：R979.1[医药卫生—药品]